Sino Biological provides four major antibody development platforms and four major protein expression platforms, which enable engagement in early development projects of multispecific antibody ...

Boster Biological Technology advances biotechnology research with its cutting-edge multiplex ELISA service, delivering precision solutions in cytokine assays, custom monoclonal antibodies, and ...

Novel CD37 antibody-drug conjugate shows promise in targeting the Achilles’ heel of acute myeloid leukemia cells.

Many cancers upregulate an amino acid transporter to fuel their growth, making this protein a promising tool in tumor ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing China-only randomised study conducted by its partner ...

antibody targeting a CTSG peptide-human leukocyte antigen (pHLA) complex and CD3. The lack of acute myeloid leukemia-specific antigens is one of the challenges for targeted immunotherapy together with ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...